Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses
Fan Huang, … , Wilson H. Miller Jr., Sonia V. del Rincón
Fan Huang, … , Wilson H. Miller Jr., Sonia V. del Rincón
Published March 9, 2021
Citation Information: J Clin Invest. 2021;131(8):e140752. https://doi.org/10.1172/JCI140752.
View: Text | PDF | Corrigendum
Research Article Oncology Article has an altmetric score of 10

Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses

  • Text
  • PDF
Abstract

Melanomas commonly undergo a phenotype switch, from a proliferative to an invasive state. Such tumor cell plasticity contributes to immunotherapy resistance; however, the mechanisms are not completely understood and thus are therapeutically unexploited. Using melanoma mouse models, we demonstrated that blocking the MNK1/2-eIF4E axis inhibited melanoma phenotype switching and sensitized melanoma to anti–PD-1 immunotherapy. We showed that phospho-eIF4E–deficient murine melanomas expressed high levels of melanocytic antigens, with similar results verified in patient melanomas. Mechanistically, we identified phospho-eIF4E–mediated translational control of NGFR, a critical effector of phenotype switching. Genetic ablation of phospho-eIF4E reprogrammed the immunosuppressive microenvironment, exemplified by lowered production of inflammatory factors, decreased PD-L1 expression on dendritic cells and myeloid-derived suppressor cells, and increased CD8+ T cell infiltrates. Finally, dual blockade of the MNK1/2-eIF4E axis and the PD-1/PD-L1 immune checkpoint demonstrated efficacy in multiple melanoma models regardless of their genomic classification. An increase in the presence of intratumoral stem-like TCF1+PD-1+CD8+ T cells, a characteristic essential for durable antitumor immunity, was detected in mice given a MNK1/2 inhibitor and anti–PD-1 therapy. Using MNK1/2 inhibitors to repress phospho-eIF4E thus offers a strategy to inhibit melanoma plasticity and improve response to anti–PD-1 immunotherapy.

Authors

Fan Huang, Christophe Gonçalves, Margarita Bartish, Joelle Rémy-Sarrazin, Mark E. Issa, Brendan Cordeiro, Qianyu Guo, Audrey Emond, Mikhael Attias, William Yang, Dany Plourde, Jie Su, Marina Godoy Gimeno, Yao Zhan, Alba Galán, Tomasz Rzymski, Milena Mazan, Magdalena Masiejczyk, Jacek Faber, Elie Khoury, Alexandre Benoit, Natascha Gagnon, David Dankort, Fabrice Journe, Ghanem E. Ghanem, Connie M. Krawczyk, H. Uri Saragovi, Ciriaco A. Piccirillo, Nahum Sonenberg, Ivan Topisirovic, Christopher E. Rudd, Wilson H. Miller Jr., Sonia V. del Rincón

×

Total citations by year

Year: 2025 2024 2023 2022 2021 Total
Citations: 4 8 10 6 2 30
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (30)

Title and authors Publication Year
Anti-PD-1 promotes a Th1-like functional adaptation of melanoma-infiltrating regulatory T cells to alleviate immunosuppression locally.
Mikhaël Attias, Fernando Alvarez, Tho-Alfakar Al-Aubodah, Roman Istomine, Paige McCallum, Fan Huang, Abrahim Sleiman, Tamiko Nishimura, Constantin Polychronakos, Sonia Rincon, Yasser Riazalhosseini, Ciriaco Piccirillo
Journal for immunotherapy of cancer 2025
eIF4F-mediated dysregulation of mRNA translation in cancer
Amiri M, Mahmood N, Tahmasebi S, Sonenberg N
RNA 2025
SENP3 inhibition suppresses hepatocellular carcinoma progression and improves the efficacy of anti-PD-1 immunotherapy.
Wang P, Qiu J, Fang Y, Li S, Liu K, Cao Y, Zhang G, Wang Z, Gu X, Wu J, Jiang C
Cell death and differentiation 2025
Guidelines for minimal reporting requirements, design and interpretation of experiments involving the use of eukaryotic dual gene expression reporters (MINDR).
Loughran G, Andreev DE, Terenin IM, Namy O, Mikl M, Yordanova MM, McManus CJ, Firth AE, Atkins JF, Fraser CS, Ignatova Z, Iwasaki S, Kufel J, Larsson O, Leidel SA, Mankin AS, Mariotti M, Tanenbaum ME, Topisirovic I, Vázquez-Laslop N, Viero G, Caliskan N, Chen Y, Clark PL, Dinman JD, Farabaugh PJ, Gilbert WV, Ivanov P, Kieft JS, Mühlemann O, Sachs MS, Shatsky IN, Sonenberg N, Steckelberg AL, Willis AE, Woodside MT, Valasek LS, Dmitriev SE, Baranov PV
Nature structural & molecular biology 2025
MNK-driven eIF4E phosphorylation as a key regulator of the fibrogenic transformation of mesenchymal cells and chronic lung allograft dysfunction
Natalie Walker, Yuta Ibuki, Aidan P. McLinden, Keizo Misumi, Dylan C. Mitchell, Gabriel Kleer, Alison M. Lock, Ragini Vittal, Nahum Sonenberg, Amanda L. Garner, Vibha N. Lama
Journal of Clinical Investigation 2024
Tunable PhenoCycler imaging of the murine pre-clinical tumour microenvironments
Abraham MJ, Goncalves C, McCallum P, Gupta V, Preston SE, Huang F, Chou H, Gagnon N, Johnson NA, Miller WH, Mann KK, del Rincon SV
Cell & Bioscience 2024
Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies
Lin X, Xie M, Yao J, Ma X, Qin L, Zhang X, Song J, Bao X, Zhang X, Zhang Y, Liu Y, Han W, Liang Y, Jing Y, Xue X
Clinical and Translational Medicine 2024
M6A-related bioinformatics analysis indicates that LRPPRC is an immune marker for ischemic stroke.
Shen L, Yue S
Scientific Reports 2024
PPM1G dephosphorylates eIF4E in control of mRNA translation and cell proliferation.
Wang P, Li Z, Kim SH, Xu H, Huang H, Yang C, Snape A, Choi JH, Bermudez S, Boivin MN, Ferry N, Karamchandani J, Nagar B, Sonenberg N
Life science alliance 2024
Unveiling the Dynamic Interplay between Cancer Stem Cells and the Tumor Microenvironment in Melanoma: Implications for Novel Therapeutic Strategies
Limonta P, Chiaramonte R, Casati L
Cancers 2024
Blocking tumor-intrinsic MNK1 kinase restricts metabolic adaptation and diminishes liver metastasis
Preston SE, Dahabieh MS, Flores González RE, Gonçalves C, Richard VR, Leibovitch M, Dakin E, Papadopoulos T, Lopez Naranjo C, McCallum PA, Huang F, Gagnon N, Perrino S, Zahedi RP, Borchers CH, Jones RG, Brodt P, Miller WH Jr, del Rincón SV
Science Advances 2024
Second-Generation Cap Analogue Prodrugs for Targeting Aberrant Eukaryotic Translation Initiation Factor 4E (eIF4E) Activity in Drug-Resistant Melanoma
Cárdenas EL, O\u2019Rourke RL, Menon A, Vega-Hernández G, Meagher J, Stuckey J, Garner AL
bioRxiv 2024
Disrupting peroxisomes alters lipid metabolism in melanoma and uncovers a novel therapeutic vulnerability in combination with MAPK-targeted therapies
Fan Huang, Feiyang Cai, Michael S Dahabieh, Kshemaka Gunawardena, Ali Talebi, Jonas Dehairs, Farah El-Turk‬, Jae Yeon Park, Christophe Goncalves, Natascha Gagnon, Jie Su, Perrine Gaub, Jean-Sébastien Joyal, John J Mitchell, Johannes Swinnen, Wilson Jr., Sonia del Rincón
Journal of Clinical Investigation 2023
Escape from NK cell tumor surveillance by NGFR-induced lipid remodeling in melanoma
Lehmann J, Caduff N, Krzywińska E, Stierli S, Salas-Bastos A, Loos B, Levesque MP, Dummer R, Stockmann C, Münz C, Diener J, Sommer L
Science Advances 2023
S-adenosylmethionine blocks tumorigenesis and with immune checkpoint inhibitor enhances anti-cancer efficacy against BRAF mutant and wildtype melanomas
Mehdi A, Attias M, Arakelian A, Szyf M, Piccirillo CA, Rabbani SA
Neoplasia (New York, N.Y.) 2023
Current challenges and future directions for engineering extracellular vesicles for heart, lung, blood and sleep diseases
Li G, Chen T, Dahlman J, Eniola\u2010Adefeso L, Ghiran IC, Kurre P, Lam WA, Lang JK, Marbán E, Martín P, Momma S, Moos M, Nelson DJ, Raffai RL, Ren X, Sluijter JP, Stott SL, Vunjak\u2010Novakovic G, Walker ND, Wang Z, Witwer KW, Yang PC, Lundberg MS, Ochocinska MJ, Wong R, Zhou G, Chan SY, Das S, Sundd P
Journal of Extracellular Vesicles 2023
Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies.
Shi ZD, Pang K, Wu ZX, Dong Y, Hao L, Qin JX, Wang W, Chen ZS, Han CH
Signal Transduction and Targeted Therapy 2023
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells.
Brina D, Ponzoni A, Troiani M, Calì B, Pasquini E, Attanasio G, Mosole S, Mirenda M, D'Ambrosio M, Colucci M, Guccini I, Revandkar A, Alajati A, Tebaldi T, Donzel D, Lauria F, Parhizgari N, Valdata A, Maddalena M, Calcinotto A, Bolis M, Rinaldi A, Barry S, Rüschoff JH, Sabbadin M, Sumanasuriya S, Crespo M, Sharp A, Yuan W, Grinu M, Boyle A, Miller C, Trotman L, Delaleu N, Fassan M, Moch H, Viero G, de Bono J, Alimonti A
Nature cancer 2023
Antigen-loaded monocyte administration and Flt3 ligand augment the antitumor efficacy of immune checkpoint blockade in a murine melanoma model
D\u2019Anniballe VM, Huang MN, Lueck BD, Nicholson LT, McFatridge I, Gunn MD
Journal of immunotherapy (Hagerstown, Md. : 1997) 2023
Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy
Cao J, Zhang Z, Zhou L, Luo M, Li L, Li B, Nice EC, He W, Zheng S, Huang C
2023
A tRF-5a fragment that regulates radiation resistance of colorectal cancer cells by targeting MKNK1.
Huang T, Chen C, Du J, Zheng Z, Ye S, Fang S, Liu K
Journal of Cellular and Molecular Medicine 2023
The expression mechanism of programmed cell death 1 ligand 1 and its role in immunomodulatory ability of mesenchymal stem cells
Chen Z, Yao MW, Ao X, Gong QJ, Yang Y, Liu JX, Lian QZ, Xu X, Zuo LJ
Chinese Journal of Traumatology 2023
Inhibiting MNK kinases promotes macrophage immunosuppressive phenotype to limit CD8+ T cell anti-tumor immunity
Thao N.D. Pham, Christina Spaulding, Mario Shields, Anastasia E Metropulos, Dhavan N. Shah, Mahmoud Khalafalla, Daniel R Principe, David Bentrem, Hidayatullah G. Munshi
JCI Insight 2022
Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition
M Berg, S del Rincón, W Miller
Journal for ImmunoTherapy of Cancer 2022
Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma
V Benboubker, F Boivin, S Dalle, J Caramel
Frontiers in immunology 2022
Overcoming Paradoxical Kinase Priming by a Novel MNK1 Inhibitor
E Bou-Petit, S Hümmer, H Alarcon, K Slobodnyuk, M Cano-Galietero, P Fuentes, P Guijarro, M Muñoz, L Suarez-Cabrera, A Santamaria, R Estrada-Tejedor, J Borrell, S y Cajal
Journal of Medicinal Chemistry 2022
Loss of YY1, a Regulator of Metabolism in Melanoma, Drives Melanoma Cell Invasiveness and Metastasis Formation
Guendisch U, Loos B, Cheng PF, Dummer R, Levesque MP, Varum S, Sommer L
Frontiers in Cell and Developmental Biology 2022
Therapeutic overexpression of miR-92a-2-5p ameliorated cardiomyocyte oxidative stress injury in the development of diabetic cardiomyopathy
Yu M, Sun Y, Shan X, Yang F, Chu G, Chen Q, Han L, Guo Z, Wang G
Cellular & Molecular Biology Letters 2022
Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy
F Huang, F Santinon, RE González, SV del Rincón
Frontiers in Oncology 2021
Optimized protocol for immunophenotyping of melanoma and tumor-bearing skin from mouse
SS Krisna, C Goncalves, N Gagnon, F Huang, D Plourde, WH Miller, JH Fritz, SV del Rincon
2021

← Previous 1 2 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 15 X users
On 2 Facebook pages
49 readers on Mendeley
See more details